Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a Nomogram to Predict Therapeutic Resistance in Metastatic Melanoma Using Longitudinal ctDNA Kinetics.

Molecular diagnosis & therapy - 1 May 2026

Miller Hunter A, Fischer Annalara G, Egger Michael E, Yaddanapudi Kavitha, Kong Maiying, Hall Melissa B, Linder Mark W

Abstract excerpt

BACKGROUND AND OBJECTIVE: Early detection of treatment resistance and progression in metastatic melanoma may improve outcomes, but current surveillance relies on intermittent radiographic imaging that may lag behind dynamic tumor biology. Circulating tumor DNA (ctDNA), a minimally invasive and increasingly validated biomarker, enables real-time disease monitoring. Longitudinal (kinetic) changes in ctDNA over time...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Melanoma

Share to Neoplasm Metastasis

Share to Nomograms

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Identifiers

PMID: 41806257
DOI: 10.1007/s40291-026-00840-x

Genes

BRAF
NRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a Nomogram to Predict Therapeutic Resistance in Metastatic Melanoma Using Longitudinal ctDNA Kinetics.PMID 41806257Read ↗

Circulating tumor DNA monitoring in advanced mutated melanoma (LIQUID-MEL)Semantic proximity Read ↗

Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic MelanomaSemantic proximity Read ↗

Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma.Semantic proximity Read ↗

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.Semantic proximity Read ↗

Dynamic ctDNA mutational complexity in melanoma patients receiving immunotherapySemantic proximity Read ↗

Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy.Semantic proximity Read ↗

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting.Semantic proximity Read ↗

Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.Semantic proximity Read ↗

Sensitivity and prognostic significance of circulating tumor DNA (ctDNA) in stage I to III malignant melanoma.Semantic proximity Read ↗

Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment.Semantic proximity Read ↗

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafuspSemantic proximity Read ↗

Longitudinal Relationship between Idylla Plasma ctBRAF V600 Mutation Detection and Tumor Burden in Patients with Metastatic Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.